

ESCMID Global 2025 Poster Presentation Schedule

Vienna, Austria | 11–15 April 2025

Sunday, 13 April | 12:00 - 13:30 CET

Poster Area | 05a. Drug discovery and new compounds mechanisms of action & spectrum, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)

Meiji	P2327	B / 7 / 38	Susceptibility of a worldwide collection of 12,613 Enterobacterales isolated during 2021-2023 to the novel combination therapy aztreonam/nacubactam
Meiji	P2328	B / 7 / 39	Activity of the novel combination therapies cefepime/nacubactam against 12,613 clinical isolates of Enterobacterales collected worldwide during 2021-2023
Pfizer	P2333	B / 7 / 44	The <i>in vitro</i> activity of aztreonam-avibactam against Enterobacterales isolates positive for metallo-beta-lactamases or serine-carbapenemases by commonly used <i>in vitro</i> diagnostic kits
Advanz	P2380	B / 8 / 43	<i>In vitro</i> activity of cefepime/enmetazobactam and comparators against ESBL and plasmid-AmpC-producing Enterobacterales

Monday, 14 April | 14:45 - 15:45 CET

Poster Area | 03a. Resistance surveillance & epidemiology: Community-acquired bacteria

GSK	P1200	A / 1 / 16	Comparison of antimicrobial susceptibility of <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> from blood and non-blood cultures: analysis from the survey of antibiotic resistance (SOAR) study, 2018-2021
Pfizer	P1203	A / 1 / 19	<i>In vitro</i> activity of ceftaroline and comparator agents against bacterial pathogens from adult patients collected during the ATLAS global surveillance programme in 2019-2023
Pfizer	P1204	A / 1 / 20	<i>In vitro</i> activity of ceftaroline against bacterial pathogens from paediatric patients collected during the ATLAS global surveillance programme in 2019-2023
Pfizer	P1223	A / 2 / 3	Distribution of macrolide resistance among <i>Streptococcus pneumoniae</i> clinical isolates collected from global populations, 2018-2019 and 2022-2023

Monday, 14 April | 12:00 - 13:30 CET

Poster Area | 03b. Resistance surveillance & epidemiology: Healthcare-associated bacteria

Merck	P1283	A / 3 / 27	<i>In vitro</i> activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and <i>Pseudomonas aeruginosa</i> isolates from geriatric patients with respiratory tract infections in the Asia/Pacific region: SMART, 2019-2023
Merck	P1284	A / 3 / 28	Activity of ceftolozane/tazobactam, imipenem/relebactam and comparators against clinical isolates of <i>Pseudomonas aeruginosa</i> from hospitalised patients in Kuwait, Oman, Qatar, and United Arab Emirates: SMART 2018-2023
Merck	P1285	A / 3 / 29	Activity of ceftolozane/tazobactam and comparators against phenotypic ESBL-producing, carbapenemase-negative clinical Enterobacterales isolates from South Africa: SMART 2018-2023
Merck	P1286	A / 3 / 30	Activity of ceftolozane/tazobactam, imipenem/relebactam and comparators against clinical isolates of <i>Pseudomonas aeruginosa</i> from hospitalised patients in Southeastern Europe: SMART 2018-2023
Merck	P1288	A / 3 / 32	Activity of imipenem/relebactam and comparators against clinical Gram-negative isolates collected in the Latin American region: SMART 2021-2023
Venatorx	P1294	A / 4 / 2	Cefepime/taniborbactam exhibits limited cross-resistance with ceftazidime/avibactam and ceftolozane/tazobactam against carbapenem-nonsusceptible Enterobacterales and multidrug-resistant <i>Pseudomonas aeruginosa</i> from Europe 2018-2023
Venatorx	P1295	A / 4 / 3	<i>In vitro</i> activity of cefepime/taniborbactam and comparators against Enterobacterales and <i>P. aeruginosa</i> collected in Europe (2018-2023) stratified by beta-lactamase carriage

Pfizer	P1317	A / 4 / 25	<i>In vitro</i> activity of aztreonam/avibactam against ceftazidime/avibactam-resistant Enterobacterales isolates collected as a part of the ATLAS global surveillance study, 2019-2023
Pfizer	P1318	A / 4 / 26	Trends in the <i>in vitro</i> activity of aztreonam/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global surveillance study in Latin America, 2019-2023
Pfizer	P1320	A / 4 / 28	Trends in the <i>in vitro</i> activity of aztreonam/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global surveillance study in Middle East/Africa, 2019-2023
Pfizer	P1321	A / 4 / 29	Trends in the <i>in vitro</i> activity of aztreonam/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global surveillance study in Asia/Pacific, 2019-2023
Pfizer	P1322	A / 4 / 30	Trends in the <i>in vitro</i> activity of aztreonam/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global surveillance study in Europe, 2019-2023
Pfizer	P1323	A / 4 / 31	<i>In vitro</i> activity of aztreonam/avibactam against Enterobacterales isolates collected from patients in intensive care units and other wards, by global region ATLAS surveillance study, 2019-2023
Pfizer	P1324	A / 4 / 32	Susceptibility of Enterobacterales collected globally to aztreonam/avibactam and comparator agents stratified by infection source: ATLAS surveillance programme 2019-2023
Pfizer	P1326	A / 4 / 34	<i>In vitro</i> activity of aztreonam/avibactam against carbapenem-resistant Enterobacterales isolates by region collected as a part of the ATLAS global surveillance study, 2019-2023
Pfizer	P1327	A / 4 / 35	Trends in the <i>In Vitro</i> Activity of Ceftazidime-Avibactam and β -lactamase Carriage Among <i>Pseudomonas aeruginosa</i> Isolates Collected as a Part of the ATLAS Global Surveillance Study in 2019-2023
Pfizer	P1328	A / 4 / 36	<i>In vitro</i> activity of ceftazidime/avibactam (CAZ-AVI) and comparators against <i>Pseudomonas aeruginosa</i> collected worldwide stratified by ICU vs non-ICU, ATLAS global surveillance programme, 2019-2023
Pfizer	P1330	A / 5 / 2	Trends in the <i>in vitro</i> activity of ceftazidime/avibactam and beta-lactamase carriage among Enterobacterales isolates collected as a part of the ATLAS global surveillance study in Europe, by subregion 2019-2023
Pfizer	P1331	A / 5 / 3	<i>In vitro</i> activity of ceftazidime/avibactam against Enterobacterales stratified by global region and year of collection, ATLAS global surveillance programme, 2018-2023
Monday, 14 April 12:00 - 13:30 CET Poster Area 03c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)			
Meiji	P1451 <i>Top Rated</i>	A / 8 / 15	<i>In vitro</i> activities of aztreonam/nacubactam and cefepime/nacubactam against carbapenemase-producing Enterobacterales collected as part of a global surveillance study in 2021-2022
Venatorx	P1468	A / 8 / 32	Cefepime/taniborbactam (FTB) epidemiological cutoff values (ECOFFs) against key Enterobacterales species and <i>Pseudomonas aeruginosa</i>
Tuesday, 15 April 12:00 - 13:30 CET Poster Area 21. New drugs and vaccines			
Antabio	P5021	A / 2 / 22	Evaluation of the activity of the novel antibiotic combination Meropenem-ANT3310 against recent multidrug-resistant Enterobacterales and <i>Acinetobacter baumannii</i> clinical isolates

Your Global Antimicrobial Partner

IHMA supports all phases of anti-infective therapy development, from discovery through commercialization. We are your essential resource for central, reference, and clinical research laboratory services worldwide.

USA • SWITZERLAND • CHINA • INDIA

www.ihma.com